Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 Co-administered With CST-107 on the Central Nervous System in Subjects With Neurodegenerative Disorders

NCT04739423 is registered in ClinicalTrials.gov with CuraSen Therapeutics, Inc. as lead sponsor.

NCT NCT04739423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04739423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 Co-administered With CST-107 on the Central Nervous System in Subjects With Neurodegenerative Disorders
Lead sponsor
CuraSen Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 28, 2021
Completion date
August 31, 2022
Enrollment
41 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment, lewy body dementia, parkinson's disease rapid eye movement sleep behavior disorder, parkinson's disease dementia